Indoco Remedies Ltd (NSE:INDOCO)

Q2 2026 Indoco Remedies Ltd Earnings Call Transcript

Nov 6, 2025 / 10:00 AM GMT

Release Date Price: ₹264.45 (-2.40%)

Transcript

Key Points

Positve

Indoco Remedies Ltd (BOM:532612) reported a significant increase in net revenues for Q2 FY26, with standalone net revenues at INR 4,293 million, reflecting an 8.8% growth compared to the previous quarter.
The company successfully launched six new products in the Indian market, enhancing its product portfolio in the anti-infective and respiratory segments.
Indoco Remedies Ltd received final ANDA approval from the US FDA for rivaroxaban tablets, indicating progress in its international regulatory approvals.
The company's API manufacturing facility at Pata Ganga was successfully inspected by the US FDA with zero observations, showcasing compliance with international standards.
Indoco Remedies Ltd's focus on manufacturing capability enhancement has started yielding results, contributing to higher productivity and competitive cost advantages.

Negative

The company faced challenges in the Europe market, with a decrease in revenues from INR 63-64 crores in Q1 to INR 54-55 crores in Q2, attributed to distribution issues and customer approvals.
Indoco Remedies Ltd's subsidiaries, FPP Holding and Warren Remedies, reported a combined loss of INR 23 crores in the quarter, impacting overall profitability.
The company continues to incur high remediation costs related to US FDA compliance, which are expected to persist for another two quarters.
Indoco Remedies Ltd's debt levels have increased significantly, with interest payments rising tenfold over the last decade, raising concerns about financial sustainability.
The OTC business under Warren Remedies is still in the investment phase, with expectations of continued losses for the next two quarters before potential break-even.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INRM.NS - Indoco Remedies Ltd
Q2 2026 Indoco Remedies Ltd Earnings Call
Nov 06, 2025 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Q2 F 526 earnings of Indoco Remedies Limited. As a reminder, all the participants' line will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing, then 0 on your touchstone phone. Please note that this conference has been recorded. I now hand the conference over to Umeshlada.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.